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Abstract
Experiments with transgenic over-expressing, and null mutant mice have determined that metallothionein-I and -II (MT-I/II)
are protective after brain injury. MT-I/II is primarily a zinc-binding protein and it is not known how it provides
neuroprotection to the injured brain or where MT-I/II acts to have its effects. MT-I/II is often expressed in the liver under
stressful conditions but to date, measurement of MT-I/II expression after brain injury has focused primarily on the injured
brain itself. In the present study we measured MT-I/II expression in the liver of mice after cryolesion brain injury by
quantitative reverse-transcriptase PCR (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) with the UC1MT antibody.
Displacement curves constructed using MT-I/II knockout (MT-I/II
2/2) mouse tissues were used to validate the ELISA. Hepatic
MT-I and MT-II mRNA levels were significantly increased within 24 hours of brain injury but hepatic MT-I/II protein levels
were not significantly increased until 3 days post injury (DPI) and were maximal at the end of the experimental period, 7 DPI.
Hepatic zinc content was measured by atomic absorption spectroscopy and was found to decrease at 1 and 3 DPI but
returned to normal by 7DPI. Zinc in the livers of MT-I/II
2/2 mice did not show a return to normal at 7 DPI which suggests
that after brain injury, MT-I/II is responsible for sequestering elevated levels of zinc to the liver. Conclusion: MT-I/II is up-
regulated in the liver after brain injury and modulates the amount of zinc that is sequestered to the liver.
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Introduction
Metallothionein (MT) is a 6–7 kDa, cysteine rich, metal binding
protein that has been shown to be neuroprotective during central
nervous system (CNS) insults in studies utilising transgenic MT-I
over-expressing animals [1–3] and MT-I/II
2/2 mice [4–11].
Interestingly, it is not MT-III, the brain-specific isoform of MT,
that provides neuroprotection [12] but the MT-I and MT-II
isoforms that provide the most neuroprotection after brain injury.
The MT-I and MT-II isoforms are often considered as a single
species (MT-I/II) due to their high homology and the inability of
primary antibodies to differentiate between the two forms. The
mechanism by which MT-I/II imparts protection to the injured
CNS is yet to be fully elucidated.
MT-I/II is expressed in many organs throughout the murine
body [13]. Numerous studies have shown that after brain injury,
the level of MT-I/II expression in the brain is increased [5,6,14–
17]. MT is chiefly a cytoplasmic protein but increased levels have
been observed in the blood of brain injured patients [18]. The
expression levels of MT-I/II in other organs after brain injury
have not been reported previously and the origin of the MT found
in the blood has not been determined. Up-regulation of MT-I/II
expression in the liver occurs in response to many stressful stimuli
such as burn injury [19–21], restraint stress [22,23], zinc challenge
[24,25], fasting and lipopolysaccharide challenge [26,27]. The
induction of liver MT-I/II expression has been shown to cause
increases in hepatic zinc content, a response that does not occur in
MT-I/II
2/2 mice [19–21,24,25]. Therefore, it appears that the
induction of hepatic MT-I/II expression results in the sequestra-
tion of zinc to the liver. Zinc sequestration from the plasma is a
characteristic of the acute phase response which is typically
induced by the cytokine interleukin(IL)-6 [28]. MT-I/II expression
is induced by increased intracellular zinc concentration, glucocor-
ticoids and IL-6 [29] which indicates that MT-I/II expression may
occur in conjunction with the acute phase response.
Altered zinc homeostasis [30] and raised concentrations of IL-6
in serum [31] have been observed in patients suffering the early
stages of brain injury. The process of hepatic MT-I/II mediated
zinc sequestration has been proposed to explain these alterations
in plasma zinc concentrations [32] but hepatic MT-I/II expression
has not been experimentally quantified after brain injury. There is
some evidence that systemic zinc status may affect the outcome of
brain injury because rats with dietary zinc deficiency preceding
experimental brain injury have greater microglial activation and
neuron death compared to injured rats on zinc-sufficient diets
[7,33]. There is also a positive association between zinc
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rate in head injured patients [34].
The aim of this study was to determine whether brain injury in
mice causes an increase in hepatic MT-I/II expression and
whether any increase in hepatic MT-I/II results in sequestration of
zinc to the liver. MT-I/II expression was measured by quantitative
reverse-transcriptase PCR (RT-PCR) and enzyme-linked immu-
nosorbent assay (ELISA). The study utilised a MT-I/II
2/2 mouse
strain that still produces MT-I and MT-II mRNAs but premature
stop codons in the open-reading-frame result in production of
greatly truncated peptides consisting of 10 and 15 amino acids
from the N-terminus, respectively [35]. This allowed for liver zinc
content after brain injury to be measured in a mouse without fully
functional MT-I/II protein.
Materials and Methods
Animals
All procedures involving animals were approved by the Animal
Experimentation Ethics Committee of the University of Tasmania
and were consistent with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes (Permit number:
A9836). 129SI/SvImJ (wild type) mice and 129S7/SvEvBrd-
Mt1
tm1Bri Mt2
tm1Bri/J (MT-I/II
2/2) mice [35] were obtained from
Jackson Laboratories. Male mice were housed with food and water
ad libitum with 12/12 hour light/dark cycling. Mice were divided
evenly into groups for the time points of 0, 1, 3 and 7 days post-
injury (DPI) and were housed in individual cages for at least 7 days
prior to surgery.
Cryolesion brain injury and sham surgery
The cryolesion injury was conducted according to the method
of Ling et al. [36]. Briefly, animals were anaesthetised for surgery
with 3% isoflurane in oxygen, delivered via muzzle mask. A 2–
3 mm incision was made in the skin above the midline of the skull.
A steel rod, 3 mm in diameter and 50 mm long that had been
cooled to equilibrium in liquid nitrogen, was held against the skull
for 6 seconds, 4 mm anterior from lambda and 2 mm right of the
midline. The incision was then sutured and the animal was
allowed to recover back in its original cage. Less than 1% of
animals showed signs of seizure within the first 24 hours after the
application of the cryolesion injury. These animals were
euthanized and excluded from the study. Zero time-point animals
were housed identically to injured mice but did not undergo
surgery before euthanasia and tissue collection. Sham surgery was
conducted in an identical manner to cryolesion surgery except that
the steel rod was not cooled in liquid nitrogen before the
procedure.
Quantitative reverse-transcriptase PCR (RT-PCR)
Anaesthetised mice were transcardially perfused with PBS. The
cryolesion injury site was dissected out of the brain using a 3 mm
biopsy punch and a liver sample was obtained by dissection and
both samples were frozen in liquid nitrogen. Liver samples were
first ground to a fine powder under liquid nitrogen, brain samples
were homogenised whole. Brain and liver samples were homog-
enised by Ultra-Turrax mechanical homogenizer (IKA) in TRI
reagent (Sigma) and RNA was extracted according to manufac-
turer’s protocol. Reverse transcription with the Superscript-III
reverse transcriptase system (Invitrogen) and quantitative PCR
with Quantitect SYBR green (Qiagen) was conducted according to
the method of Brettingham-Moore et al. [37]. Oligonucleotide
primers are detailed in table 1. The MT-I and MT-II primer sets
were designed to bind to the cDNA for the transcripts from both
wild type and MT-I/II
2/2 mice, which still produce MT-I and
MT-II transcripts but have premature stop codons inserted to
prevent complete protein translation. Standard curves were
created using known quantities of each PCR product and were
used to determine the original cDNA copy number at an arbitrary
fluorescence threshold (CT). b-actin mRNA was used as the house
keeping gene and MT-I and MT-II mRNA copy numbers was
divided by b-actin copy number, to standardise the data set.
Protein homogenisation
Brain biopsies and liver samples were ground to powder under
liquid nitrogen and homogenised in 150 mM NaCl, 20 mM Tris-
HCl, 1% Igepal, pH 7.6 with EDTA-free Halt-protease inhibitor
cocktail (Thermo Scientific) with an Ultra-Turrax mechanical
homogenizer (IKA). Samples were centrifuged at 10 000g for
10 minutes and the supernatant was retained for assay. Protein
concentration was obtained by Bradford assay [38].
UC1MT competitive ELISA
MT-IIA (HPLC-purified rabbit MT-IIA saturated with 7 Zn
2+
ions per molecule, Bestenbalt, Estonia) was coated to a Nunclon
delta surface 96-well microplate (Nunc) in 50 mM Na2CO3 solution
at 4uC overnight on an orbital shaker. All subsequent stages took
place at room temperature. Following a 5 minute rinse in wash
buffer consisting of 0.05% Tween-20 (Sigma) in PBS, wells were
blocked with 150 ml casein solution (2.5%, pH 7.4) for 30 minutes.
The wells were washed again in wash buffer for 5 minutes. Mouse
tissue homogenates or plasma samples were diluted in wash buffer to
achievea proteinconcentration of 0.1 mg/ml and standardMT-IIA
solutions were made up in wash buffer. Samples and standards were
applied to the plate in triplicate or quadruplicate in 50 ml aliquots.
Primaryantibody(UC1MTmouse anti-MT-I/II,Assaydesigns)was
diluted 1:5000 (40 ng/ml, final concentration) in ELISA wash buffer
and applied to sample- or standard-containing wells for 1 hour. The
plate was rinsed 3 times with wash buffer. Secondary antibody
(Dako, Goat anti-mouse IgG-horse radish peroxidase (HRP)
conjugate) was diluted 1:2000 in ELISA wash buffer and applied
toeachwellin50 mlaliquotsfor1 hour.Theplatewasrinsed 3times
with wash buffer. 50 ml TMB peroxidase substrate (KPL) was
applied for 1 hour. The reaction was terminated with 50 mlo f1M
phosphoric acid and the absorbance was measured at 450 nm.
Calculation of sample MT-I/II concentrations from the standard
curve was conducted with 4-parameter logistic modelling according
tothemethodofFindlayandDillard[39].Displacementcurveswere
generated by serial dilution of MT-IIA standard solutions in tissue
homogenate from MT-I/II
2/2 mice. Several curves were created
for each tissue type with varying concentrations of total protein.
Table 1. Oligonucleotide primer sets used for quantitative
RT-PCR with genbank accession numbers.
Primer Sequence (59 -3 9) Accession No.
b-actin Fwd GTCCACCTTCCAGCAGATGT NM_007393.3
Rev AGGGAGACCAAAGCCTTCAT
MT-I Fwd GCTGTCCTCTAAGCGTCACC NM_013602.3
Rev AGGAGCAGCAGCTCTTCTTG
MT-II Fwd CAAACCGATCTCTCGTCGAT NM_008630.2
Rev AGGAGCAGCAGCTTTTCTTG
doi:10.1371/journal.pone.0031185.t001
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reactivity
Microplate wells were coated with 50 ml of standard curve
solutions for MT-IIA and MT-III (HPLC-purified human MT-III
saturated with 7 Zn
2+ ions per molecule, Bestenbalt, Estonia)
which were made up in 50 mM Na2CO3 and incubated overnight
at 4uC on an orbital shaker. Following a 5 minute rinse in wash
buffer, wells were blocked with 150 ml casein solution (2.5%,
pH 7.4) for 30 minutes. The wells were washed again in wash
buffer for 5 minutes. UC1MT primary antibody was diluted
1:1000 in ELISA wash buffer and applied to wells and incubated
for 1 hour. The plate was rinsed for 3 times with wash buffer.
HRP-conjugated secondary antibody was diluted 1:2000 in ELISA
wash buffer and applied to each well in 50 ml aliquots for 1 hour.
After rinsing with wash buffer, TMB peroxidase substrate (KPL)
was incubated in the wells in 50 ml aliquots for 1 hour. The
reaction was terminated by addition of 50 ml of 1 M phosphoric
acid and the absorbance was measured at 450 nm.
Radioimmunoassay for corticosterone
Blood was obtained from mice at 0, 1, 3 or 7 DPI. Mice were
anaesthetised by being placed in a chamber containing 5%
isoflurane in oxygen. As soon as anaesthesia was achieved, 0.5 ml
of blood was obtained via cardiac puncture with syringes
containing 20 ml of 5000 units/ml heparin solution (Sigma).
Plasma was obtained by centrifugation at 14 0006g for 5 minutes.
Assay of plasma corticosterone was conducted as described in
Pankhurst et al. [40]. Standard solutions of unlabelled corticoste-
rone were prepared by serial dilution in assay buffer and were
added directly to assay tubes. A standard curve was generated to
calculate the concentration of corticosterone in each sample. All
samples and standards were assayed in duplicate. Extraction
efficiency for mouse plasma was determined by adding a known
quantity of
3H-corticosterone to plasma samples pooled from
several mice and the assay concentrations were adjusted
accordingly.
Liver zinc assay by atomic absorption spectroscopy
Liver samples from uninjured and injured mice were dissected
out and freeze-clamped in liquid nitrogen. Each sample was
ground to a fine power under liquid nitrogen with a mortar and
pestle. The powdered liver was homogenised in 1 ml of MilliQ
(Millipore) water with a Potter-Elvehjem homogeniser. The
homogenate was transferred to a pre-weighed tube and was
lyophilised. The gross weight of the tube was measured after
lyophilisation to calculate the net weight of the sample.
Lyophilised liver samples were dissolved in 3.5 ml of 70% nitric
acid (Trace select, Fluka) by heating to 70uC for 1 hour. The
samples were diluted with 3 ml of MilliQ water and 0.5 ml of 30%
hydrogen peroxide to fully oxidise thiols (Trace select, Fluka).
Centrifugation at 20006g for 20 minutes was required to remove a
small quantity of insoluble matter. Zinc concentration in each
sample was assayed on an atomic absorption spectrometer (GBC
Avanta S). Zinc concentration of the sample solutions was
determined by comparison to the absorbance of zinc sulphate
standard solutions prepared in 35% nitric acid and 2.14%
hydrogen peroxide in MilliQ water.
Statistical analysis
Homogeneity of variances between groups within each data set
was determined with Levene’s test. The Box-Cox test was used to
determine the appropriate transformation for data sets with
heterogeneous variances between groups. Comparisons of MT-I
and MT-II mRNA, MT-I/II protein expression and liver zinc
content were conducted by 1-way ANOVA with Tukey’s B post-
hoc test. The comparison of corticosterone between wild type and
MT-I/II
2/2 mice was conducted with 2-way ANOVA with
Tukey’s B post-hoc test on the factors of time after injury and
strain of mouse. For all experiments, differences were considered
statistically significant where p,0.05.
Results
UC1MT ELISA optimisation and validation
We optimised the MT-I/II ELISA procedure published by
Emeny et al. [41]. By trialling different coating concentrations of
recombinant MT-IIA and different antibody dilutions, it was
determined that the optimal coating concentration for the
microplate was 100 ng/ml MT-IIA. Optimal primary antibody
dilution of 1:5000 (40 ng/ml IgG final concentration) and
secondary antibody dilution of 1:2000 (0.5 mg/ml final IgG
concentration) yielded the highest sensitivity in the ELISA (data
not shown). Figure 1 shows the standard curve of the ELISA with
4-parameter logistic curve fitted. A cut-off for the detection limit of
was set at 10 ng/ml MT and yet this required 500-fold lower levels
of primary antibody than the procedure of Emeny et al. [41]. The
coefficient of variation was used to determine the range of the
intra-assay variability of the ELISA and was calculated to be 3.46–
10.33%cv.
When the UC1MT antibody was initially characterised for its
ability to detect MT-I and MT-II by ELISA [42], the discovery of
MT-III was relatively recent and no test for cross-reactivity of MT-
III with this antibody has since been published. It was necessary to
demonstrate that the UC1MT ELISA is specific for MT-I/II and
does not cross-react with MT-III, the brain-specific MT isoform
(figure 2). It is apparent from the curves that the UC1MT
antibody displays little cross reactivity with MT-III.
Displacement curves were set up to determine if matrix effects
that could interfere with the ELISA were present in mouse brain
or liver tissue homogenates (figure 3). Such curves have not been
published previously for the UC1MT ELISA technique. The term
‘‘matrix effects’’ relates to substances in complex biological
samples that do not directly cause false-positive detection in an
immunoassay but have the capacity to displace the antibody-
antigen interaction [43,44]. Displacement curves are similar to
standard curves except that serial dilution of the analyte is
performed in analyte-free matrix, in this case tissue homogenate
Figure 1. Standard curve generated by the UC1MT competitive
ELISA with 4-parameter logistic curve fitted. Each point shown is
the average of 4 quadruplicate standards.
doi:10.1371/journal.pone.0031185.g001
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2/2 mouse brain and liver was used. Using MT-I/
II-free brain and liver homogenates with total protein concentra-
tion of 0.1 mg/ml or 0.01 mg/ml, we observed no deviation of the
slope of the displacement curves from the standard curve which
indicates that no matrix effects are present under these assay
conditions, in these tissues. We have determined that concentra-
tions higher than 0.1 mg/ml begin to interfere with the assay in
most of the tissue types tested.
MT-I and MT-II induction in liver post-brain injury
In the site of the brain injury, expression of MT-I and MT-II
mRNA and MT-I/II protein was increased within 1 DPI (data not
shown), as has been observed previously [5,6,14–17]. Quantitative
RT-PCR revealed that liver MT-I and MT-II mRNA increases
after brain injury (figure 4). Wild type mice showed a 4.9 fold
increase in MT-I mRNA at 1 DPI in the liver, followed by
subsequent decreases at 3 and 7 DPI. MT-II mRNA was
significantly increased at 1 DPI but was maximal at 3 DPI with
a 40.4 fold increase in expression over uninjured levels.
Interestingly, increases in MT-I/II protein levels, as determined
by competitive ELISA, were delayed and did not show significant
increases until 3 DPI with maximal protein expression at 7 DPI
(figure 5). The possibility of MT-I/II protein increases from zero
to 1 DPI could not be investigated because the quantities detected
at both of these time points were less than or equal to the detection
limit of the assay.
The nature of the targeted disruption of the MT-I and MT-II
genes in the MT-I/II
2/2 mouse strain allows for the measurement
of gene transcription in the absence of expression of the full-length
proteins. In MT-I/II
2/2 mice the level of MT-I and MT-II
mRNA in the liver after brain injury is reduced compared to wild
type mice (figure 4).
Plasma corticosterone concentration increases after
cryolesion brain injury
The glucocorticoid, corticosterone, is the primary stress
hormone produced by the adrenal gland in rodents, and has an
analogous role to cortisol in humans. Thus, we hypothesised that
corticosterone may influence hepatic MT-I/II synthesis as part of
a systemic response to brain injury. To test this in our model,
plasma corticosterone levels were assayed by radioimmunoassay in
both wild type and MT-I/II
2/2 mice, with injury, without injury
and with sham injury surgery (figure 6A). No significant differences
in plasma corticosterone were found between wild type and MT-
I/II
2/2 mice before or after injury as determined by 2-way
ANOVA. However, it was determined that there were significant
and comparable increases in plasma corticosterone concentrations
in cryolesioned and sham-injured animals. This indicates that
animal handling is the most likely responsible for the increases in
plasma corticosterone rather than the brain injury. Quantitative
RT-PCR was carried out on liver samples from sham-injured
animals but no significant increases in MT-I or MT-II mRNA
expression were observed after sham surgery, despite the ability of
the procedure to increase plasma corticosterone (figure 6B). In
summary, the increases in plasma corticosterone after brain injury
or sham surgery are not sufficient to induce hepatic MT-I/II
expression alone and it is likely that another process is responsible
for the increased hepatic expression of MT-I/II after brain injury.
Liver zinc post-injury
Liver zinc was assayed by atomic absorption spectroscopy in
MT-I/II
2/2 and wild type mice to determine if hepatic MT-I/II
sequesters zinc after brain injury. In the absence of injury there is
no significant difference in the liver zinc content between the two
mouse strains, indicating that MT-I/II normally makes a minor
contribution to total zinc binding. Brain injury caused a slight
decrease in liver zinc content at 1 and 3 DPI in both strains of
mouse (figure 7), suggesting release of zinc from non-MT-I/II
source. However, at 7 DPI significant differences between wild
type and MT-I/II
2/2 mice were observed. In the wild-type mice
we saw a recovery in zinc content to a level that was not
significantly different to the level seen pre-injury. This increase in
Figure 2. Cross-reactivity of the UC1MT antibody for MT-III was
tested by direct ELISA. Comparison of the standard curves for MT-IIA
(blue lines) and MT-III (red lines) demonstrate UC1MT has very little if
any cross-reactivity for MT-III. Data are expressed as the mean of
triplicate measurements (error bars=SEM).
doi:10.1371/journal.pone.0031185.g002
Figure 3. Displacement curves for MT-IIA in MT-I/II
2/2 mouse
brain homogenate (A) and MT-I/II
2/2 mouse liver homogenate
(B). Displacement curves constructed in solutions with protein content
of 0.01 mg/ml and 0.1 mg/ml are parallel to the standard curve
constructed in PBS. Therefore, no matrix effects were observed at these
concentrations, in these tissues (n=3, error bars=SEM).
doi:10.1371/journal.pone.0031185.g003
Brain Injury and Hepatic Metallothionein
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31185liver zinc content at 7 DPI corresponds precisely to the period
when dramatic increases in MT-I/II protein levels were observed
(figure 5). In contrast, no significant recovery in hepatic zinc was
observed for MT-I/II
2/2 mice at 7 DPI which strongly implies
that MT-I/II is responsible for this process.
Discussion
The observations presented herein are consistent with a model
whereby zinc is released from cellular stores in the liver following
brain injury, and that increased MT-I/II expression then functions
to return zinc to the liver. In human studies it has been found that
serum zinc levels are decreased upon admission of head injury
patients to hospital [30]. Zinc excretion via urine was found not to
be the cause and it was later hypothesised that MT-I/II expression
in the liver was sequestering zinc from the plasma [32]. Our data
suggest that, in mice, zinc is initially released from the liver and
that MT-I/II expression is then up-regulated in order to restore
hepatic zinc to pre-injury levels. Because the liver is a relatively
large organ, this response may also have the ability to affect zinc
availability in other organs. It has been shown previously that MT-
I/II induction by the liver has the ability to buffer sudden, systemic
increases in free zinc after zinc injection [24]. In the present study,
the zinc composition of the diet remained constant but it is clear
that zinc is becoming mobilised from the liver. The effect that
disruption to zinc homeostasis has on the progression of brain
injury is not well understood.
The factors that directly induce MT-I and MT-II mRNA
expression have been identified as increased intracellular free zinc
concentration via interaction with metal transcription factor-1
(MTF-1), IL-6 signalling and glucocorticoid receptor activation
[29]. The data in the present study indicated that the
Figure 4. Expression of MT-I and MT-II mRNA in the liver of wild type and MT-I/II
2/2 mice after brain injury was quantified by RT-
PCR. (A) MT-I mRNA expression showed its greatest increase at 1 DPI and 3 DPI in wild type mice. (B) MT-II mRNA was increased at 1 DPI in wild type
mice but was at peak levels at 3 DPI. MT-I/II
2/2 mice were unable to increase MT-I and MT-II mRNA levels to the same extent as wild type mice.
Groups that share lower case letters are not significantly different from each other (for both graphs; n=6–7, error bars=SEM).
doi:10.1371/journal.pone.0031185.g004
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inducing an increase in MT-I or MT-II mRNA expression in the
liver. In vitro, glucocorticoids are capable of increasing levels of
MT-I/II mRNA in hepatocyte cultures [45]. However, in vivo
experiments investigating the induction of hepatic MT-I/II by
restraint stress suggest that glucocorticoids are responsible for
altering the translation of mRNA into protein but that IL-6
signalling is the factor responsible for inducing MT-I/II mRNA,
not glucocorticoids [22]. It remains a possibility that corticosterone
enhances the expression of hepatic MT-I/II synthesis after brain
injury, even if it is not solely responsible for MT induction. The
cytokine IL-6 has been found to be increased in the serum of head-
injured patients [31]. Using this cryolesion injury model, increased
IL-6 mRNA expression can be detected at the site of brain injury
but IL-6 protein was not readily detected in plasma by cytokine
assay, nor was there de novo synthesis of IL-6 mRNA detected in
the liver (unpublished observations). Therefore IL-6 is unlikely to
play a role in the induction of hepatic MT-I/II in our brain injury
model.
Figure 5. Liver MT-I/II protein levels after cryolesion injury to
the brain were assayed by UC1MT ELISA in wild type mice.
Hepatic MT-I/II protein levels were not increased until 3 DPI and showed
a further increase at 7 DPI. Groups that share lower case letters are not
significantly different from each other (n=7, error bars=SEM).
signalling mechanism is involved.
doi:10.1371/journal.pone.0031185.g005
Figure 6. Corticosterone concentrations in plasma after cryolesion injury to the brain were assayed by RIA in wild type and MT-I/II
2/2
mice (A). No significant differences were found between the mouse strains. There was a significant increase in plasma corticosterone after cryolesion
injury and sham surgery to a similar extent. Sham surgery does not induce a significant change in hepatic MT-I or MT-II mRNA expression (B). Time
points that share letters are not significantly different (n=5, error bars=SEM).
doi:10.1371/journal.pone.0031185.g006
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responsible for inducing hepatic MT-I/II expression after brain
injury, further supporting the hypothesis that brain injury disrupts
systemic zinc homeostasis. We provide the following hypothesis to
explain the increases in MT-I and MT-II mRNA expression
despite decreases in total zinc. Zinc is transported out of cells as
free ions but the majority of zinc in cells is bound to zinc-binding
proteins. Oxidative stress can displace zinc from metalloproteins
[46], effectively increasing the free zinc concentration inside the
affected cell. Free zinc would be susceptible to efflux transport, but
would also be available to bind to metal-transcription factor-1, a
complex which facilitates MT-I and MT-II gene transcription
[reviewed in 29]. Head injury to rats has been shown to induce a
whole body oxidative stress within 15 minutes of the injury [47].
MT-I/II itself, is a zinc-binding metalloprotein and it is susceptible
to oxidation leading to zinc liberation [48,49]. Liberation of zinc
from proteins and subsequent transport from hepatocytes is
consistent with the decreased hepatic zinc content observed at 1
DPI in the present study. Hence, an oxidative mechanism provides
one hypothesis to explain brain injury mediated decreases in total
hepatic zinc levels with simultaneous increases in MT-I and MT-II
mRNA expression.
High expression of MT-I/II is thought to decrease cytoplasmic
concentrations of free zinc. However, it has been shown that under
normal physiological conditions, the amount of zinc bound to
MT-I/II is below maximum capacity [50]. For hepatic MT-I/II to
be involved in zinc sequestration, the ratio of MT-I/II to cellular
zinc is expected to be much higher to create a sufficient diffusion
gradient to favour the entry, and retention, of zinc in the hepatic
cytoplasm. High levels of MT-I/II protein could also provide
negative feedback for MT-I and MT-II mRNA expression by
binding free-zinc and limiting the availability of cytoplasmic zinc
to MTF-1. This would explain the low levels of mRNA transcript
observed at 7 DPI, despite high levels of MT-I/II protein. The fact
that MT-I/II
2/2 mice have altered expression of MT-I and MT-
II mRNA is in accordance with our hypothesis that MT-I/II is one
of the storage proteins for zinc that can play a role in its own
regulation when zinc is liberated from proteins. However, it
warrants mention that cellular processes known collectively as
nonsense-mediated mRNA decay exist to remove abnormal
transcripts [51] and may be removing the MT-I and MT-II
transcripts in MT-I/II
2/2 mice at a faster rate than normal
because of the premature stop codons they contain. Reporter
assays in cells isolated from MT-I/II
2/2 mice may be required in
future experiments to determine which of these possibilities is
occurring.
In conclusion, we have shown that brain injury, like many
severe perturbations to an animal, causes an increase in hepatic
MT-I/II expression which leads to sequestration of zinc to the
liver. This shuttling of zinc may affect the hepatic processes after
brain injury but may also have implications for systemic zinc
availability after brain injury. Given that the mechanism by which
MT-I/II is neuroprotective after brain injury is unclear, these
findings introduce the possibility that MT-I/II expressed outside
the central nervous system could impact upon brain injury.
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